https://www.selleckchem.com/pr....oducts/oligomycin-a.
onfirm these findings and to identify the best and easiest methods for monitoring BC during nutritional intervention and oncological therapies.The LRRK2 gene has rare (p.G2019S) and common risk variants for Parkinson's disease (PD). DNM3 has previously been reported as a genetic modifier of the age at onset in PD patients carrying the LRRK2 p.G2019S mutation. We analyzed this effect in a new cohort of LRRK2 p.G2019S heterozygotes (n = 724) and meta-analyzed our data with previously published data (n = 754). VAMP4 is in close proxim
Like
Comment
Share
